Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
about
Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsSodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesDapagliflozin efficacy and safety: a perspective review.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsCase Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesAmelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Novel Agents for the Treatment of Type 2 Diabetes.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusIn-Silico Trials for Glucose Control in Hospitalized Patients with Type 2 DiabetesOnce daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapyEmpagliflozin/linagliptin single-tablet combination: first-in-class treatment optionCharacteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment optionsImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Dapagliflozin combination therapy in type 2 diabetes mellitus.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.Implications of the EMPA-REG Trial for Clinical Care and Research.Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects.Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss.The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.
P2860
Q26752815-D371894F-E9D5-4FD4-99A5-D1C2038207DEQ27010669-619C620B-DD86-45DE-B23F-3D8B11DFB9FEQ33626249-125FF589-DFDB-4672-88B9-D7A747D676CDQ34105064-17FC1561-7592-4508-961E-BBE4AFD56318Q34198692-CE5084BF-CA58-4A0A-BC89-EB4A96C07E0FQ34514280-30D1435E-3052-4A0D-8E64-E37F66AF65B8Q34973750-FA962E2F-4400-41E4-A0BB-69841B94A2D6Q35133751-B8EB7B13-9E95-47AF-BA26-A265AA898D5FQ35194026-32515637-8342-4D49-B9F9-FF2CA446F9A0Q35780861-191D8EEC-EB67-4C44-8A57-31CD5B3202E2Q35852679-11BB03A5-23B7-45E9-98BD-C56CE769AD6AQ35887931-9F2CC3A5-7D28-41C2-A992-966BDE112924Q35910421-79738CF5-1020-4FFD-B0C8-0D9F3FD22103Q36179371-C77F9570-3B51-42FB-B308-428997450A1DQ36232787-0DC09397-1B17-4AE0-8CF3-41BD32E68251Q36345951-0C168525-00F2-44F2-9423-5B15442281CDQ36509957-B54AAE9F-4208-4532-8A2F-FE7D4116C1C7Q36937697-6CF62119-4DC7-4378-93E6-00FAE0C5DAEAQ37227410-C7DC7128-06B4-45AF-A9A4-72EA24D55BCBQ37308941-38CDF15A-9858-4631-B24C-D27080D587CEQ37677733-4BDA6654-FFBE-440C-82D0-96842935B44DQ38201162-BC4AE0FF-64D3-46C7-816B-AE4B504D0D8DQ38254252-053A9CBB-768D-4B4E-AEC3-0FD2B4FCEFB8Q38270203-53C14CEB-9F86-4B97-B921-A82A4FF36B02Q38330456-F3680F66-1D18-44BC-983A-CFC86D9B78CDQ38429845-CE44CF60-0102-4DF5-86B6-EE4DC579CADFQ38452883-A80D0F51-7496-4F84-99C6-7BF50CDEDEB1Q38524435-6D65EB84-4B4D-475E-97AB-7BD0A7625DCEQ38602771-DE242A6A-49A6-43D6-A6F6-A8A2E4EA4A5BQ38634051-CF2BC2A6-589D-48EC-AE47-870625037D0BQ38635763-8C199E4D-4E02-4B51-97F4-41A015581790Q38777020-300FFA18-F7EB-48D4-8D9D-B3A5E2D08ED0Q38798623-E9AC9015-C337-4192-B5DD-9A476EF68ABEQ38800979-D4D9598B-ABE4-4B88-9804-FBDBE5B52F31Q38804903-55884644-BF1E-44BD-B9D5-7AD4663C4FE2Q38827756-138BD66F-22FA-496D-96E0-653352DB5ED2Q38834997-1A7BDD48-6BD0-426F-88ED-6661CCD6D9AAQ38906470-A04154A8-5FA4-4613-BFF2-241C95D870F7Q38932322-24221666-3C9B-4ECC-8A1F-60689DC4B50CQ38936746-62521F1B-2D83-4328-8FAA-F38C87B90A47
P2860
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of renal gluc ...... subjects with type 2 diabetes
@en
Characterization of renal gluc ...... subjects with type 2 diabetes.
@nl
type
label
Characterization of renal gluc ...... subjects with type 2 diabetes
@en
Characterization of renal gluc ...... subjects with type 2 diabetes.
@nl
prefLabel
Characterization of renal gluc ...... subjects with type 2 diabetes
@en
Characterization of renal gluc ...... subjects with type 2 diabetes.
@nl
P2093
P2860
P921
P356
P1433
P1476
Characterization of renal gluc ...... subjects with type 2 diabetes
@en
P2093
Agatha Ching
Bruce R Leslie
David W Boulton
Frank P LaCreta
Linda A Morrow
Marc Pfister
Sreeneeranj Kasichayanula
Steven C Griffen
Xiaoni Liu
P2860
P304
P356
10.2337/DC13-0387
P407
P577
2013-06-04T00:00:00Z